New scan could spot breast cancer protein without needle

NCT ID NCT03991260

Completed Diagnosis Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested a new radioactive imaging agent called 99mTc-ADAPT6 to see if it can detect HER2 protein in breast cancer tumors using SPECT scans. Sixteen women with primary breast cancer received a single injection, followed by scans over six hours. The goal was to compare the imaging results with standard biopsy tests to see if the agent can accurately identify HER2 status.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Technetium-99m-labelled ADAPT6
What this could lead to: If successful, this could provide a non-invasive way to determine HER2 status in breast cancer, potentially guiding treatment without needing a biopsy.
What could go wrong: This was a very small, early-phase study with only 16 participants, so results may not apply to all patients. The imaging agent may not accurately distinguish HER2-positive from HER2-negative tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

TomskNRMC

Tomsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.